Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.34 |
| ▸ | TUBB | P07437 | 2/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473751 | 0.87 | TUBB4A (0.32) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3483532 | 0.75 | CYP2A6 (0.46) | MAPT | |
| SCHEMBL3816084 | 0.72 | CYP2A6 (0.32) | — | |
| SCHEMBL29968024 | 0.72 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4477774 | 0.71 | MAPT (0.35) | MAPT | |
| SCHEMBL4065377 | 0.71 | CYP2A6 (0.34) | — | |
| SCHEMBL3817449 | 0.71 | — | — | |
| SCHEMBL1402281 | 0.70 | IMPDH2 (0.42) | MAPT | |
| SCHEMBL18936126 | 0.68 | CYP2A6 (0.51) | — | |
| SCHEMBL3483341 | 0.68 | HDAC3 (0.37) | TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563713-A | 4-phenyl substituted isoxazole compound and application thereof in antihistamine medicine | 王兴理 | 2019-12-13 | — | — | CN | claimed |
| EP-1778639-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| CN-110563713-A | 4-phenyl substituted isoxazole compound and application thereof in antihistamine medicine | 王兴理 | 2019-12-13 | — | — | CN | disclosed |
| US-9499531-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150274713-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | CURIA GLOBAL, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9085531-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140243524-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8741901-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130005965-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-03 | — | — | US | disclosed |
| US-8236796-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1778639-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | CURIA GLOBAL, INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | OPRK1, OPRL1, OPRD1 | TUBB4A 2096/4885TUBB 2825/4885TUBA3C 2600/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | TUBB4A 3786/4885TUBB 3921/4885TUBA3C 3766/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | TUBB4A 1355/4885TUBB 1489/4885TUBA3C 1049/4885 |
| US-20130005965-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | TUBB4A 219/4885TUBB 496/4885TUBA3C 858/4885 |
| US-20150274713-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | TUBB4A 219/4885TUBB 496/4885TUBA3C 858/4885 |
| US-20140243524-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | TUBB4A 219/4885TUBB 496/4885TUBA3C 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.